久久综合九色综合欧美狠狠_欧美成人精品一区二区久久久_体内射精欧洲精品_一级a国产片免费看_一区二区三区欧美动漫在线_国语精品免费自产拍在线观看_久久精品免视看国产成人_2019精品手机国产品在线,97在线精品国自产拍中文,国产精品一区二区久久不卡,麻豆精品国产自产在线观看,国产精品原创中文巨作av,亚洲免费网站观看视频,亚洲国产精品无码久久久久久曰,久久久精品国产亚洲成人满18免费网站,99久久综合狠狠综合久久最近高清影院免费观看,国产亚洲美日韩AV中文字幕无码成人,无码国产亚洲日韩国精品视频一区二区三区

供貨周期	現(xiàn)貨	規(guī)格	T-25 Flask
貨號(hào)	CBP73192	應(yīng)用領(lǐng)域	生物產(chǎn)業(yè)
主要用途	僅限科研使用

CBP73192
I. Introduction
Cell Line Name：	SLC34A2-ROS1 [G2032R]/BaF3
Host Cell:	Ba/F3
Stability:	16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application:	Anti-proliferation assay and PD assay
Freeze Medium:	90% FBS+10% DMSO
Complete Culture Medium:	RPMI-1640+10%FBS
Mycoplasma Status:	Negative

II.Background
Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012). In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015). Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample. ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).

III. Representative Data
1. WB of SLC34A2-ROS1 [G2032R]/BaF3expression Figure 1. Protein Expression of ROS1 detected by antibody
2.Sanger Sequencing of SLC34A2-ROS1 Fusion and G2032R mutation Figure 2. SLC34A2-ROS1 Fusion Figure 3. ROS1 p.G2032R
3. Anti-proliferation assay
Figure 4. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1 [G2032R]/BaF3 Stable Cell Line.